Natco Pharma Limited
NATCOPHARM · Pharma · NSE
₹1,087
Current Market Price
Fair Value (DCF)
₹1,809
Margin of Safety
+66.4%
Updated 2d ago
YieldIQ Score
77/100
Piotroski F-Score
5/9
Economic Moat
Wide
Confidence
35%
ROE
24.8%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹0.19 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
30.0%
Return on capital employed
EV / EBITDA
8.0×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
135.8×
EBIT covers interest
Current Ratio
5.59×
Short-term liquidity
Asset Turnover
0.42×
Revenue per ₹ of assets
Revenue CAGR (3Y)
35.6%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,087
Bear case
₹916.56
MoS -18.6%
Base case
₹1,808.63
MoS +39.9%
Bull case
₹2,299.1
MoS +52.7%
Ratio Trends
NATCOPHARM · last 8 annual periods
ROE
24.8%
ROCE
32.2%
Operating Margin
—
Debt / Equity
0.04×
PE
14.1×
EV / EBITDA
9.8×
Historical Financials
NATCOPHARM · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1654 Cr | ₹1768 Cr | ₹2697 Cr | ₹3979 Cr | ₹4412 Cr | +27.8% |
| EBITDA | — | ₹358 Cr | ₹1035 Cr | ₹1872 Cr | ₹2544 Cr | +63.3% |
| EBIT | ₹404 Cr | ₹169 Cr | ₹327 Cr | ₹437 Cr | — | +2.0% |
| PAT | ₹310 Cr | ₹139 Cr | ₹715 Cr | ₹1388 Cr | ₹1885 Cr | +57.1% |
| EPS (diluted) | ₹16.96 | ₹7.63 | ₹15.11 | ₹19.49 | — | +3.5% |
| CFO | ₹184 Cr | ₹57.7 Cr | ₹849 Cr | ₹1196 Cr | ₹1697 Cr | +74.4% |
| CapEx | — | — | — | — | ₹-512 Cr | — |
| FCF | — | — | — | — | ₹1185 Cr | +0.0% |
| Total Assets | — | ₹5109 Cr | ₹5657 Cr | ₹6554 Cr | ₹8631 Cr | +14.0% |
| Total Debt | — | — | ₹165 Cr | ₹363 Cr | ₹279 Cr | +14.1% |
| Shareholders' Equity | — | — | ₹4874 Cr | ₹5592 Cr | ₹7612 Cr | +11.8% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
NATCOPHARM vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| ERIS Eris Lifesciences Limited | -60.8% | 56 | Data Limited | 10.8% | — |
| ASTRAZEN ASTRAZEN | — | — | Pending | 15.0% | — |
| WOCKPHARMA WOCKPHARMA | — | — | Pending | -1.0% | — |
| GLAND GLAND | — | — | Pending | 7.6% | — |
| EMCURE EMCURE | — | — | Pending | 14.7% | — |
Click a ticker to view its fair-value analysis.
Dividend History
29 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹30.50/sh
Last payout
2026-02-18
₹1.50
Peak payout
₹7.00
Trailing yield
0.46%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Natco Pharma Limited (NATCOPHARM.NS) trades at 1087.00 vs a model fair value of 1808.63, a gap of 66.4%. Piotroski F-score: 5/9. Moat lab...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of NATCOPHARM →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for NATCOPHARM →
Compare
Head-to-head with peers
Compare NATCOPHARM side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse NATCOPHARMNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.